跳至主要内容
临床试验/JPRN-jRCTs031230646
JPRN-jRCTs031230646招募中2 期

An exploratory randomized controlled trial of the clinical efficacy of anamorelin hydrochloride in patients after radical surgery for upper gastric cancer and esophagogastric junction cancer - a phase II trial

Matsumoto Yasunori0 个研究点目标入组 30 人开始时间: 2024年2月20日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Adults 18 years of age or older at the time of consent
  • 2) Patients with a histological diagnosis of gastric adenocarcinoma or adenocarcinoma of the esophagogastric junction
  • 3) Patients who have undergone a gastrectomy or total gastrectomy as radical surgical treatment
  • 4) Patients with ECOG Performance Status 0-2
  • 5) Patients with preserved major organ function (heart, lungs, liver, kidneys, etc.)
  • 6) Patients who can start taking the study drug within 8 weeks after surgery
  • 7) Patients who have been fully informed of the study and who have given written consent of their own free will after full understanding of the study.

排除标准

  • ) Patients who have difficulty taking food orally
  • 2) Patients with other cancers requiring treatment
  • 3) Patients who have undergone preoperative chemotherapy
  • 4) Patients with postoperative complications (Clavien-Dindo classification IIIa or higher) from gastric cancer surgery
  • 5) Patients for whom postoperative adjuvant chemotherapy is recommended in the guidelines for the treatment of gastric cancer.
  • 6) Patients with hypersensitivity to anamorelin hydrochloride in the past
  • 7) Patients who received anamorelin hydrochloride within 12 weeks prior to the start of study drug administration
  • 8) Patients with severe conduction disturbances (e.g., complete atrioventricular block)
  • 9)Patients with poorly controlled diabetes
  • 10) Patients receiving the following drugs
  • clarithromycin, itraconazole, voriconazole, ritonavir-containing preparations, cobicistat-containing preparations, encitrelvir fumarate
  • 11)Patients who are pregnant, possibly pregnant, within 28 days postpartum, or lactating
  • 12) Other patients who are judged by the principal investigator or subinvestigator to be inappropriate for the safe conduct of this study.

研究者

发起方
Matsumoto Yasunori

相似试验